Premium
P4‐160: Imaging Marker of Neuroinflammation Predicts Progression in Alzheimer's Disease
Author(s) -
Wang Qing,
Wang Yong,
Christensen Jon,
Shimony Joshua S.,
Liu Jingxia,
Fagan Anne M.,
Cairns Nigel J.,
Ances Beau,
Morris John C.,
Benzinger Tammie L.S.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2252
Subject(s) - neuroinflammation , white matter , microglia , medicine , diffusion mri , pathology , amyloid (mycology) , psychology , inflammation , disease , neuroscience , magnetic resonance imaging , radiology
Screen success rate was very high in sites who recruited from their known subjects and they mainly randomized pAD subjects. Sites reaching out to a broader population through referrals, advertisement and other initiatives had lower screen success rates but managed to randomize most of the ARAD subjects. From all subjects with biomarker information collected, amyloid positivity was found in 72% of subjects with CDR1⁄40.5 (pAD) and in 32% of subjects with CDR1⁄40 (ARAD). Conclusions: There is a high screening burden for sites involved in the identification of subjects with early AD. Differences in recruitment strategies resulted in distinct rates of pAD and ARAD subjects. Tailored strategies for pAD and ARAD may increase recruitment success.